Ionis Pharmaceuticals unveiled results from a survey conducted by The Harris Poll showing that 91% of surveyed adults living ...

Fintel reports that on April 30, 2025, HC Wainwright & Co. downgraded their outlook for SpringWorks Therapeutics ...

Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

Fintel reports that on April 29, 2025, Guggenheim downgraded their outlook for SpringWorks Therapeutics (NasdaqGS:SWTX) from ...

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in ...

Merck KGaA acquires SpringWorks Therapeutics, Inc. for $3.9B, boosting its pipeline with OGSIVEO & GOMEKLI. Click for more on ...

SpringWorks sells two rare tumors drugs in the US and has two precision oncology drugs in early-stage development.

Portugal's Galp will be gradually restarting units at its Sines oil refinery over the coming days after the major Iberian ...

Merck KGaA plans to acquire SpringWorks Therapeutics (NASDAQ:SWTX) for approximately $3.9 billion, aiming to enhance its ...

Merck is acquiring the American cancer specialist Springworks for three billion euros. Discover all the details of the ...

The biggest M&A activity of the year arrived in the form of Merck KGaA’s earlier-disclosed agreement to buy Springworks Therapeutics Inc. for $47 per share in cash, which represents an equity value of ...